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Abstract: RLS is a common sleep disorder with distinctive clinical features. The prevalence 
of RLS in Caucasians and North Americans ranges from 5% to 10%. However, only some of 
these subjects (almost the 3% of the general population) report being affected by a frequent and 
severe form of the sleep disorder. RLS is diagnosed clinically by means of four internationally 
recognized criteria that summarize the main characteristics of the sleep disorder. Besides the 
essential criteria, supportive and associated features of RLS have been established by experts in 
order to help physicians treat patients with doubtful symptoms. Several clinical conditions may 
mimic this sleep disorder. In order to increase the sensibility and speciﬁ  city of RLS diagnosis, 
doctors should perform a meticulous patient history and then an accurate physical and neurologi-
cal examination. Dopamine agonists are recognized as the preferred ﬁ  rst-line treatment for RLS. 
Rotigotine is a non-ergoline dopamine agonist with selectivity for D1, D2 and D3 receptors. 
The drug is administered via transdermal patches which release rotigotine for 24 hours. Four 
clinical trials demonstrated that this compound is able to improve RLS symptomatology with 
few and moderate adverse events. Head to head trials are required to compare the efﬁ  cacy and 
tolerability of rotigotine with other dopamine agonists administered via oral intake. Rotigotine 
has been approved by the FDA and EMEA for Parkinson’s disease. For the treatment of mod-
erate to severe idiopathic RLS, rotigotine has been recommended for approval by the EMEA 
and is under review by the FDA.
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Introduction
Restless legs syndrome (RLS) is included in the most recent version of the Interna-
tional Classiﬁ  cation of Sleep Disorders (ICSD-2) among the sleep-related movement 
disorders.1 Patients with RLS report an urge to move their legs caused or accompanied 
by unpleasant sensations in the affected limbs. The urge to move appears at rest and is 
improved by leg movements. RLS symptoms show a classic circadian pattern appear-
ing or worsening in the evening or during the night.2
To date, the underlying pathophysiology of RLS is still not fully understood. 
The most accredited hypothesis recognizes an involvement of the diencephalic 
A11 dopaminergic neurons. It seems that these dopaminergic cells are able to 
modulate the nociceptive afferents by means of their projections into the dorsal 
horns of the spinal cord.3,4 Speciﬁ  c lesions in A11 nuclei of rats induced some 
features similar to those of human RLS with a long latency of sleep, a reduced 
sleep time, and several episodes of standing upright. As for RLS symptomatology, 
these abnormal behaviors decreased after pramipexole treatment.5 In a subsequent 
study, locomotor activity was evaluated in four groups, consisting of: normal mice, 
mice with A11 lesions, mice fed with a low-iron diet, and mice with A11 lesions 
combined with iron deprivation. Locomotor activity was increased in both the 
A11-lesioned and iron-deprived mice compared with normal mice. In the group Neuropsychiatric Disease and Treatment 2009:5 68
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combining A11 lesions with iron deprivation, the mice 
showed further augmented motor activity.6 An increased 
locomotor activity during either the end of the active or 
during the inactive period, similar to human RLS, has 
been recently observed in other animal studies character-
ized by dietary iron deprivation.7,8 The role of iron status 
on RLS pathophysiology has been largely evaluated also 
in humans. A reduced brain iron content was noticed in 
RLS patients during autopsies, magnetic resonance and 
transcranical ultrasound imaging studies, and cerebrospinal 
ﬂ  uid analyses.9–13 Clinical conditions, such as pregnancy, 
end-stage renal disease and gastrectomy, that are able to 
compromise iron availability, favor the occurrence of RLS. 
In fact, patients with decreased peripheral iron stores have 
a higher risk of reduced iron status in the central nervous 
system than the general population. Brain iron deﬁ  ciency 
might cause abnormalities in dopaminergic systems and, 
consequently, induce RLS symptoms.14
RLS can be distinguished in primary and secondary 
forms. To diagnose a primary form of RLS, all the clinical 
conditions known to favor the sleep disorder have to be ruled 
out by laboratory, physical, neurological and neurophysi-
ological examinations. The main characteristic of primary 
RLS is a positive family history;15 thus a genetic basis for 
this form has been hypothesized.16 Linkage studies dem-
onstrated the presence of 5 different loci associated with 
RLS (RLS1 on chromosome 12q, RLS2 on chromosome 
14q, RLS3 on chromosome 9p, RLS4 on chromosome 
2q, RLS5 on chromosome 20p).17–26 A part from RLS1 
that showed a pseudodominant pattern of inheritance, the 
remaining loci were identiﬁ  ed under the assumption of an 
autosomal dominant model. In addition, other 3 loci on 
chromosome 19q, 4q and 17p were recently identiﬁ  ed.27,28 
The large number of loci associated with RLS point to 
genetic heterogeneity of the sleep disorder. The role of these 
genome-wide linkage studies in improving our knowledge 
of RLS has been very limited. More interesting information 
came from genome-wide association studies. These analyses 
identiﬁ  ed variants within intronic and intergenic regions of 
MEIS1, BTBD9, MAP2K5/LBOXCOR1 and PTPRD.29–31 
Subjects carrying one allele-risk have a 50% increased risk 
of developing RLS.
Iron deficiency, end-stage renal disease, peripheral 
neuropathy, use of neuroleptics and pregnancy represent 
the clinical conditions identiﬁ  ed as risk factors for RLS.32 
Recently, type 2 diabetes mellitus and multiple sclerosis 
have been recognized as being able to favor RLS.33,34 Patients 
affected by secondary forms of the sleep disorder report a 
low frequency of positive family history of RLS, a late age 
of onset of RLS, and the antecedence of onset of the main 
clinical condition to RLS onset. In addition, a treatment able 
to remove the main clinical condition (such as iron supple-
ments and kidney transplantation) may produce a complete 
remission of RLS symptomatology.
In patients affected by RLS with a serum ferritin concen-
tration lower than 50 μg/L, iron therapy should be started. 
Since oral iron is not well absorbed by the gastrointestinal 
tract, intravenous iron infusions are considered more effec-
tive in treating this secondary form of RLS.35–37 However, a 
recent randomized, double-blind, placebo-controlled study 
of 1000 mg intravenous iron sucrose failed to demonstrate 
signiﬁ  cant improvements in RLS symptoms.38 Moreover, in 
almost 3% of subjects treated with intravenous iron dextran 
an anaphylactoid reaction may occur. This risk is increased 
in patients affected by autoimmune and rheumatoid dis-
orders. In addition, if iron therapy (oral or intravenous) 
is started, long-term monitoring for hemochromatosis is 
necessary.
In Caucasian and North American population the preva-
lence of RLS ranges from 5% to 10%.32 In 2005 the REST 
study showed that only a part of the general population 
(almost 3% of the subjects enrolled in 5 European coun-
tries and in the United States) was affected by severe RLS 
symptoms occurring more than 2 days per week.39 In these 
subjects RLS symptoms impair nocturnal rest, causing dif-
ﬁ  culties in falling asleep and frequent nocturnal awakenings. 
Thus, these patients may complain of tiredness and daytime 
sleepiness, and their family and social lives may be adversely 
affected.39 Some subjects report sensory discomfort also 
when sitting or lying down for a prolonged period during the 
day. A compromised quality of life (QoL) and an abnormal 
psychological status are common consequences of severe 
RLS.40,41 In addition, recent studies showed that RLS is able 
to induce cognitive dysfunction42 and to increase the risk of 
cardiovascular disease.43
In order to detect patients affected by a severe form of 
RLS, physicians should focus their attention on 3 differ-
ent features of the sleep disorder: intensity, frequency and 
consequences (sleep quality, daytime tiredness, mood and 
quality of life) of RLS symptoms. A recent paper by Happe 
et al showed that the desire for treatment among patients 
is determined by a previously known RLS diagnosis, daily 
symptoms and poor sleep.44 Unfortunately, the validated 
scales measuring intensity of RLS symptoms are able to 
assess only speciﬁ  c characteristics of RLS, for example, the 
John Hopkins Restless Legs Severity Scale addresses when Neuropsychiatric Disease and Treatment 2009:5 69
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RLS symptoms occur over 24 hours, while the RLS-6 scales 
evaluate the severity of RLS symptoms during different 
time periods of the day. The International RLS Rating Scale 
(IRLS) seems to cover more appropriately the clinical spec-
trum of RLS, it has some limitations, being prone to a placebo 
effect (see section “Management of RLS with rotigotine”) 
and only partially evaluating RLS consequences on QoL.
Patients with a severe form of RLS require a therapeutic 
approach. Non-pharmacological treatment, based on physi-
cal exercise, sleep hygiene and lifestyle interventions, seems 
to be useful, but randomized controlled studies are lacking. 
However, many pharmacological trials on RLS have been 
performed. On the basis of this increasing scientiﬁ  c literature, 
several evidence-based reviews have been recently carried 
out and practice recommendations proposed.45–51 Differently 
from evidence-based reviews that mention speciﬁ  c drugs 
and speciﬁ  c dosages for RLS, practice recommendations 
recognize levodopa and dopamine agonists as the preferred 
ﬁ  rst-line treatments for RLS.
Both ergoline and non-ergoline dopamine agonists were 
able to control RLS symptomatology.50 Since several cases 
of pleural, pericardial and retroperitoneal ﬁ  brosis, and of 
valvular heart disease have been reported in patients treated 
with ergot-derived compounds for Parkinson’s disease, the 
most common pharmacological approach to RLS is repre-
sented by non-ergoline dopamine agonists.52,53
Some patients treated with dopaminergic agents for RLS 
may report a worsening of their clinical symptoms, a condi-
tion known as augmentation. Augmentation is characterized 
by: (i) an earlier time of symptom onset in the evening or 
in the afternoon; (ii) a shorter latency to symptom onset 
when the patient is at rest; (iii) an increase in the intensity of 
RLS symptoms; iv) a shortening of the period of relief after 
administration; (v) an expansion of symptoms to previously 
unaffected body parts.54 To date, only 2 head to head trials 
have compared the rate of augmentation under levodopa 
and dopamine agonists (pergolide and cabergoline). In both 
studies, the presence of augmentation was more common 
using levodopa than dopamine agonists.55,56 On the basis of 
these results, dopamine agonists are preferred to treat RLS.
The ﬁ  rst part of this paper is focused on the diagnostic 
criteria and differential diagnosis of RLS, while in the second 
part we review the chemical and clinical characteristics of 
rotigotine in the management of RLS.
Diagnosis of RLS
Diagnosis of RLS is clinical and based on the characteristics 
of the sleep-related movement disorder. These characteristics 
may be summarized in 3 main components: i) sensory, 
ii) motor, and iii) circadian.
Sensory component
Patients with RLS may report uncomfortable and unpleas-
ant sensations in their legs. Several terms (“creeping”, 
“crawling”, “tingling”, “cramping”, “stubbing”, “tension”, 
“pulling”, “itching”, “burning”, “electric current-like”, 
“pain”), often bizarre (“like water ﬂ  owing”, “like worms 
or bugs crawling under the skin”, “Elvis legs”, “soda bub-
bling in the veins”), are used by sufferers to describe their 
RLS symptoms. However, several RLS patients may be 
affected by an urge to move their limbs not associated with 
sensory discomfort or, sometimes, they report being unable 
to separate out the motor restlessness from their disagreeable 
sensations.2 In nearly all RLS patients the sensory component 
is reported as “deep” and involves both legs. Apart from the 
legs, also the arms, and less frequently the trunk and face, 
may be involved with RLS symptoms.57–63
Motor component
The urge to move, associated or not with the unpleasant sen-
sations, appears when RLS patients are at rest and is relieved 
by movement. Thus, sensory and motor components of RLS 
show a strong relationship. This link can be explained by the 
role of movement in modulating sensory perceptions.64 Since 
rest and immobility can induce the unpleasant sensations in 
RLS sufferers, Montplaisir et al developed a neurophysi-
ological test, the Suggested Immobilization Test (SIT), in 
order to help physicians diagnose the sleep disorder. During 
a 60-minute period the subject is asked to remain in bed with 
legs outstretched and eyes opened.65 Compared with normal 
subjects, RLS patients experience a signiﬁ  cantly higher dis-
comfort as estimated by means of a visual analog scale.66 In 
order to relieve the sensory component, RLS patients perform 
several motor patterns, such as turning in bed, stretching, 
massaging or rubbing the lower limbs, walking around the 
bedroom, having a warm or cold bath.
In addition, as part of the motor component, RLS patients 
present involuntary, stereotyped and periodic movements of 
the lower extremities, known as periodic limb movements 
(PLM).67 PLM are characterized by the extension of the big toe 
with ﬂ  exion of the ankle, knee and sometimes the hip. These 
movements can be detected both during sleep and while awake 
(PLMS and PLMW). Although PLM have a high sensitiv-
ity (more than 85% of people with RLS presenting them),67 
they show a low speciﬁ  city for RLS. In fact, PLM have been 
described in patients with several other sleep disorders, such Neuropsychiatric Disease and Treatment 2009:5 70
Merlino et al
as obstructive sleep apnea syndrome, narcolepsy and REM 
behavior disorder, and also in the elderly, as a normal variant. 
PLM detection is based on neurophysiological techniques, usu-
ally on polysomnography. In order to be included into a PLM 
sequence, each limb movement has to last between 0.5 and 
5 seconds during sleep and between 0.5 and 10 seconds during 
wakefulness, recur with a periodicity of 5 to 90 seconds (gener-
ally 20–40 seconds) and occur in a series of 4 or more similar 
movements.68 PLMS/h (number of leg movements events 
occurring during sleep that meet PLM criteria, divided by the 
number of hours of sleep with leg movement recording) and 
PLMW/h (number of leg movements events occurring during 
wakefulness that meet PLM criteria, divided by the number 
of hours of wakefulness with leg movement recording) are 
the two measures used to assess the severity of PLM. Since 
PLMS are often related to EEG arousal, the PLM-arousal index 
(number of leg movements events occurring during sleep that 
meet PLM criteria and have an associated arousal divided by 
the number of hours of sleep with leg movement and arousal 
recording) is scored as well. Due to the fact that several healthy 
patients without sleep disorders show a PLMS/h above 10,69 
the ICSD-2 suggests that only indexes 15 should be consid-
ered as pathological among adults.1 During SIT, RLS patients 
demonstrate a greater number of leg movements, which fulﬁ  l 
criteria for PLMW, compared healthy controls.70
Circadian component
In RLS patients the unpleasant sensations and PLM show a 
characteristic circadian pattern across the 24 hours, with a max-
imum from 23:00 to 03:00 and a minimum between 09:00 and 
14:00.71–73 This circadian pattern is opposite to the temperature 
proﬁ  le, whereas it is in concordance with the melatonin one.72,73 
A recent study attempted to dissociate the effects of immobil-
ity duration during SIT from those of intrinsic nycthemeral 
variations on symptoms of RLS. This investigation showed 
that the worsening of RLS symptoms due to immobility is 
closely linked to their intrinsic circadian variation.74 The tim-
ing of the core temperature cycle and the circadian proﬁ  les 
of melatonin, prolactin, cortisol, and growth hormone are 
normal among RLS patients, thus almost excluding a primary 
circadian rhythm disorder.71,72,75,76 To date, the exact role of 
either sleep drive or circadian variation in RLS symptoms is 
unknown. Similarly, mechanisms (such as circadian variations 
of serum iron, co-factor of tyrosine-hydroxylase [rate-limiting 
enzyme in the production of dopamine], and dopamine itself) 
involved in the circadian component of RLS have been recently 
hypothesized, but these suggestions must be conﬁ  rmed by 
further future experiments.77,78
In 1995 the International RLS Study Group assembled 
the main components of RLS into 4 diagnostic criteria that 
were updated in 2003. Besides the essential criteria, the Inter-
national RLS Study Group detected 3 supportive features: 
(i) a positive family history for RLS; (ii) a good response 
to dopaminergic therapy; (iii) the presence of PLM), and 
3 associated features (i) a chronic clinical course of RLS; 
(ii) the disturbance of sleep onset and maintenance of sleep; 
(iii) normal ﬁ  ndings on physical and neurological examina-
tions in primary RLS.2 Physicians may use the supportive 
features for patients with doubtful symptomatology, while 
associated features are useful to reinforce a diagnosis of RLS. 
Table 1 summarizes the essential criteria, and the supportive 
and associated features of RLS.
Table 1 Diagnostic criteria for RLS (as deﬁ  ned in2)
Essential criteria
1.   An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move 
is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs)
2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting
3.   The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the 
activity continues
4.   The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (when 
symptoms are very severe, the worsening at night may not be noticeable but must have been previously present)
Supportive features
1.  Positive family history (40%–60% in patients with primary RLS; 12%–13% in patients with secondary RLS)16
2.  Positive response to dopaminergic therapy (80%–90% after a single dose of 100/25 levodopa/benserazide)100
3.  Periodic limb movements (during wakefulness or sleep) (Observed in 80%–85% of RLS patients)67
Associated features
1.  Natural clinical course
2. Sleep  disturbance
3.  Medical evaluation/physical examinationNeuropsychiatric Disease and Treatment 2009:5 71
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Table 2 Differential diagnosis of RLS
Disorders characterized by motor restlessness or by an abnormal motor pattern at sleep onset or during sleep
Disorder General features Discriminating features
Neuroleptic-induced akathisia EC1 (only restlessness), EC2 EC1 (no unpleasant sensations), EC3 (often not 
effective; whole body-rocking movements or 
marching in place), EC4. SF3 (infrequent). Abuse 
of neuroleptics
Hypotensive akathisia EC1, EC2 (only while sitting), EC3 EC2 (none while lying down), EC4. Signs 
of orthostatic hypotension
Restlessness with volitional movements EC1 (only restlessness) EC1 (no unpleasant sensations). SF2. Signs 
of anxiety
Hypnagogic jerks EC4.   AF2 (if very severe) EC1, EC2, EC3. SF3
Propriospinal myoclonus EC4.   AF2 EC1, EC2, EC3. SF2
Periodic limb movements disorder EC4. SF2, SF3.   AF2 EC1, EC2, EC3
Disorders able to cause leg pains 
or discomfort
Nocturnal leg cramps EC1 (painful sensations associated 
with muscular contraction), 
EC2, EC3 (stretching), EC4
EC1 (no restlessness). SF2, SF3
Painful legs and moving toes EC1 (painful sensations) EC3 (often no effective), EC4
Positional discomfort EC1, EC2, EC3 EC4
Meralgia paresthetica EC1, EC2, EC3 EC4
Peripheral neuropathy EC1 (painful sensations), EC2 EC1 (no restlessness), EC3, EC4. SF2.   AF3
Myelopathy and radiculopathy EC1, EC2, EC3 EC1 (no restlessness), EC4. SF2.   AF3
Vascular or neurogenic claudication EC1 EC1 (no restlessness), EC2, EC3, EC4. SF2.   AF3
Venous disorders EC1, EC2, EC3 EC2 (especially while standing up), EC4. SF2.   AF3
Vesper’s curse EC1 (pain and paresthesias), EC4 EC1 (no restlessness). SF2.   AF3
Abbreviations: EC, essential criteria; SF, supported features; AF, associated features (as deﬁ  ned in2).
The number following each acronym refers to the corresponding criterion.
Differential diagnosis of RLS
Several clinical conditions can mimic RLS.79 In a large 
multicenter study performed in a primary care population (the 
REST primary care study), the authors noticed that only a 
few patients (52/209 or 24.9%), who satisﬁ  ed all the essential 
criteria for RLS reporting symptoms at least twice-weekly 
with moderate or severe impact on QoL, were correctly 
diagnosed by their physicians. Varicose veins/venous dis-
order, back/spinal damage or problem, diabetic neuropathy, 
depression, myalgia and neuropathy/radiculopathy were the 
other most common diagnoses.80 These data demonstrate that 
the sensitivity of the essential criteria for RLS is lower than 
100%. False negative diagnosis of RLS is frequent when 
the examiner is not familiar with this sleep disorder and, 
consequently, does not understand the criteria correctly. 
A higher awareness of RLS is needed among primary care 
physicians. On the other hand, an erroneous diagnosis of RLS 
is likely when other conditions mimicking the sleep disorder 
are present. In fact, several disorders can apparently fulﬁ  l all 
4 essential criteria for RLS; thus an accurate patient history 
and physical evaluation is mandatory in order to increase the 
speciﬁ  city of RLS diagnosis.
Bearing in mind the 3 main components of RLS, clini-
cal conditions mimicking the sleep disorder can be distin-
guished in 2 main groups: (i) disorders characterized by 
motor restlessness or by an abnormal motor pattern at sleep 
onset or during sleep and (ii) disorders able to cause leg 
pains or discomfort. Table 2 summarizes these disturbances, 
emphasizing their discriminative features that are useful in 
differentiating them from RLS.
Disorders characterized by motor 
restlessness or by an abnormal motor 
pattern at sleep onset or during sleep
Neuroleptic-induced akathisia
Patients treated for a long time with neuroleptics may 
present an inner restlessness involving the whole body, 
not associated with sensory discomfort. In order to satisfy Neuropsychiatric Disease and Treatment 2009:5 72
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their urge to move, these subjects perform body-rocking 
movements or start marching in place. Sometimes, these 
motor patterns are not effective in improving restlessness. 
Differently from RLS, the neuroleptic-induced akathisia 
does not show a circadian pattern and has a signiﬁ  cantly 
lower rate of PLM.
Hypotensive akathisia
A clinical condition characterized by restlessness involv-
ing lower extremities and occurring in the sitting position. 
This disorder is due to autonomic failure, and thus can be 
associated with orthostatic hypotension. Patients develop the 
adaptive habit of restless leg movements in order to reduce 
drops in blood pressure while sitting. In the lying down posi-
tion clinical symptoms disappear. Symptoms of hypotensive 
akathisia do not worsen in the evening or at night.
Restlessness with volitional movements
Repetitive volitional movements in the lower extremities 
may occur in patients with anxiety and/or insomnia. These 
motor activities are not associated with sensory discomfort 
and are treated with benzodiazepines.
Hypnagogic jerks
Sudden physiologic jerks of all or part of the body that occur 
during the transition between wake and sleep. Occasionally 
these myoclonic activations are so frequent and severe that 
affected patients report difﬁ  culty in sleep onset. Associated 
sensory discomfort and PLM are not present.
Propriospinal myoclonus
Massive symmetric jerks not associated with sensory 
discomfort, arising from axial muscles and spreading 
rostrally and caudally. These myoclonic movements are 
spinal-cord-mediated and may be related to spinal damage. 
They appear during relaxation and result in severe sleep-onset 
insomnia. Benzodiazepines and anticonvulsants are used as 
pharmacological therapy.
Periodic limb movements disorder
Sleep-related motor disorder characterized by the repeti-
tive occurrence of PLM during sleep and able to cause 
fragmented nocturnal rest or excessive daytime sleepiness. 
Differently from individuals suffering from PLM associ-
ated to RLS, these patients do not complain of restlessness 
or disagreeable sensations in the legs. However, similarly 
to RLS, dopaminergic agents are effective in decreasing 
PLM number.
Disorders able to cause legs pain 
or discomfort
Nocturnal leg cramps
Painful sensations due to prolonged muscular contractions 
appearing during sleep and involving speciﬁ  c muscles, 
generally the calf ones. Motor restlessness and PLM are 
not present. Differently from RLS patients, subjects with 
leg cramps present a palpable tightening of leg muscles. 
Leg cramps do not respond to dopaminergic agents and are 
alleviated by stretching and not by movement.
Painful legs and moving toes
Uncommon syndrome in which patients refer to painful 
sensations in the feet associated with slow, involuntary and 
repetitive toe movements. These movements often do not 
improve the sensory discomfort and do not show a circadian 
pattern.
Positional discomfort
This comes from prolonged sitting or lying down positions. 
A simple change of position relieves the sensory discomfort. 
A circadian pattern is absent.
Meralgia paresthetica
Postural positions during sitting and lying down may cause 
a compression of lateral femoral cutaneous nerve with par-
esthesia. As positional discomfort, a change of position is 
able to improve the clinical symptomatology and a circadian 
pattern of the disturbance is lacking.
Peripheral neuropathy
Patients with peripheral neuropathy frequently report pain-
ful sensations, without restlessness, in the upper and lower 
extremities. As RLS, these sensations may impair at rest, 
but do not improve with sustained movements and rarely 
worsen in the evening or at night. Peripheral neuropathy 
does not respond to dopaminergic therapy. Signs of poly-
neuropathy should be detected by means of a neurological 
examination.
Myelopathy and radiculopathy
Spinal or radicular damages may reveal themselves as dys-
esthesia and painful sensations, but no restlessness, in the 
lower extremities. These complaints frequently occur in the 
sitting or lying down position and are improved by move-
ment. Differently from RLS, a circadian pattern of the clinical 
symptoms and a positive response to dopaminergic agents 
are lacking. A physical examination might reveal atrophic 
changes of musculature with skin abnormalities.Neuropsychiatric Disease and Treatment 2009:5 73
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Vascular or neurogenic claudication
Clinical conditions characterized by dysesthesia and painful 
sensations, but no restlessness, increasing in intensity dur-
ing leg movements and relieved at rest. These symptoms do 
not worsen in the evening or at night. Skin alterations are 
common.
Venous disorders
A sensory discomfort that is impaired at rest, particularly in 
standing up position, and improved by movement may be due 
to venous stasis. Differently from RLS, venous disorders do 
not show a circadian pattern and a positive response to dopa-
minergics. Skin alterations and edema might be observed 
during physical examination.
Vesper’s curse
An increase in the right atrium ﬁ  ll ing pressure due to chronic 
heart failure causes a delay in venous circulation. This clini-
cal condition may lead to an increase in the pressure and 
enlargement of the lumbar veins with a relative narrowing of 
the spinal canal and re  duced oxygenation. Affected patients 
report lumbosacral and associated leg pain and paresthesias 
generally occurring in the afternoon and evening. PLM can be 
observed. Vesper’s curse does not respond to dopaminergic 
agents. Cardiopulmonary alterations are common and should 
be detected during physical examination.
Physicians should consider that some clinical conditions 
able to mimic RLS can also induce secondary forms of RLS. 
In fact, variants of RLS due to neuroleptic abuse and peripheral 
neuropathy have been identiﬁ  ed. Although systematic studies 
are lacking, several case-reports show the occurrence of RLS 
in patients treated for a long time with antipsychotics.81–85 
Pathophysiology of this symptomatic form of RLS should be 
related to the drug’s blocking effects on dopamine receptors. 
Although both typical and atypical neuroleptics seem to be 
able to cause the sleep disorder, drugs with less blocking action 
on D2 receptor, such as clozapine and quetiapine, might be less 
dangerous. The association between RLS and peripheral neu-
ropathy was initially described by Ekbom and, subsequently, 
conﬁ  rmed by many studies.86–93 These studies revealed that the 
axonal-sensory and the small-ﬁ  ber polyneuropathies are the 
most common causes of RLS.89–93 An imbalanced equilibrium 
in the dorsal horn of the spinal grey matter among the excit-
atory nociceptive inputs, due to the peripheral neuropathy, and 
the inhibitory ones descending from the diencephalon might 
explain the occurrence of RLS in the course of peripheral 
neuropathy.33 Differently from primary RLS, patients affected 
by RLS due to polyneuropathy identify the sensory discomfort 
in the legs as painful sensations.33,92
Management of RLS with rotigotine
Rotigotine is a non-ergoline dopamine agonist with simi-
lar actions to those of bromocriptine, but in contrast to 
bromocriptine (a dopamine D2-agonist) it also has agonist 
properties at D1 and D3 receptors.
Chemistry
The chemical name of rotigotine is S-(-)-2-(N-propyl-N-
2-thienylethylamino)-5-hydroxytetralin hydrocloryde. The 
empirical formula is C19H25NOS. The molecular weight is 
315.48 Da.
Pharmacodynamics
Rotigotine demonstrates D1, D2 and D3 agonist activity, with 
an almost 15-fold higher afﬁ  nity for the D2 receptor than for 
the D1 receptor. Rotigotine improved motor deﬁ  cits in animal 
models of Parkinson’s disease, including when administered 
transdermally. The efﬁ  cacy of rotigotine in controlling RLS 
symptomatology might be due to the fact that this compound 
is able to restore dopaminergic transmission. Rotigotine has 
also α2 adrenergic receptor antagonistic and 5-HT1a agonistic 
activity.
Pharmacokinetics and metabolism
Rotigotine is given as transdermal patches because of a low 
oral bioavailability due to an extensive ﬁ  rst-pass effect. This 
transdermal delivery system bypasses the gut wall and the 
hepatic circulation, and provides stable plasma levels. On 
average, approximately 45% of the rotigotine from the patch 
is released within 24 hours (0.2 mg/cm2), independently of 
patch size. When single doses of 40 cm2 systems are applied 
to the trunk, there is an average lag time of approximately 
3 hours until the drug is detected in plasma (range 1–8 hours). 
Tmin occurs most commonly between 0 and 7 hours post dose. 
Tmax typically occurs between 15 to 18 hours post dose but 
can occur from 4 to 27 hours post dose. After removal of the 
patch, plasma levels decrease and have a terminal half-life of 
5 to 7 hours. Rotigotine displays dose-proportionality over a 
daily dose range of 2 mg/24 hours to 8 mg/24 hours. In the 
clinical studies of rotigotine effectiveness, the transdermal 
system application site was rotated from day to day (abdo-
men, thigh, hip, ﬂ  ank, shoulder, or upper arm) and the mean 
measured plasma concentrations of rotigotine were stable 
over the 6 months of maintenance treatment. In healthy 
subjects, steady-state plasma concentrations of rotigotine 
were achieved within 2 to 3 days of daily dosing. Relative 
bioavailability for the different application sites at steady-
state was evaluated in subjects with Parkinson’s disease. Neuropsychiatric Disease and Treatment 2009:5 74
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Differences in bioavailability ranged from less than 1% 
(abdomen vs hip) to 64% (shoulder vs thigh), with shoulder 
application showing higher bioavailability. As rotigotine is 
administered transdermally, food does not affect absorption 
of the product, so it can be administered without regard to the 
timing of meals. The weight normalized apparent volume of 
distribution (Vd/F) in humans is approximately 84 L/kg after 
repeated dose administration. The binding of rotigotine to 
human plasma proteins is approximately 92% in vitro and 
89.5% in vivo. Rotigotine is extensively metabolized by con-
jugation and N-dealkylation. Rotigotine is primarily excreted 
in urine (∼71%) as inactive conjugates of the parent compound 
and N-desalkyl metabolites. A small amount of unconjugated 
rotigotine is renally eliminated (1% of the absorbed dose).
Administration
Patch sizes used in clinical trials in patients with idiopathic 
RLS were 2.5 cm2 (rotigotine dosage 0.5 mg/24 hours; total 
drug content 1.125 mg), 5 cm2 (1 mg/24 hours; 2.25 mg), 
10 cm2 (2 mg/24 hours; 4.5 mg), 15 cm2 (3 mg/24 hours; 
6.75 mg), and 20 cm2 (4 mg/24 hours; 9.0 mg). Patches are 
applied once daily and should be replaced every 24 hours with 
the new patch applied to a different site. When given for idio-
pathic RLS, the initial rotigotine dose is 0.5 mg/24 hours (patch 
size 2.5 cm2), increased in weekly steps of 2 mg, if necessary. 
A maximum dose of 4 mg/24 hours (patch size 20 cm2) is used 
to treat RLS symptoms. Higher dosages (until 16 mg/24 hours) 
are used in patients with early or advanced Parkinson’s disease. 
Treatment with rotigotine should be withdrawn gradually; the 
daily dose should be reduced in steps of 2 mg every other day 
until complete withdrawal is achieved. An abrupt withdrawal 
of the drug might lead to a syndrome resembling neuroleptic 
malignant syndrome or akinetic crises.
Special population
Hepatic insufﬁ  ciency
The effect of impaired hepatic function on the pharmacoki-
netics of rotigotine has been studied in subjects with moder-
ate impairment of hepatic function. There were no relevant 
changes in rotigotine plasma concentrations. No dose adjust-
ment is necessary in subjects with moderate impairment of 
hepatic function. No information is available on subjects with 
severe impairment of hepatic function; however, in these 
patients rotigotine should be used with caution.
Renal failure
The effect of renal function on rotigotine pharmacokinetics 
has been studied in subjects with mild to severe impairment 
of renal function including subjects requiring dialysis 
compared to healthy subjects. There were no relevant changes 
in rotigotine plasma concentrations. In subjects with severe 
renal impairment not on dialysis (ie, creatinine clearance 
15 to 30 mL/min), exposure to rotigotine conjugates was 
doubled. Rotigotine concentrations did not decrease in 
patients with renal failure undergoing hemodialysis and the 
drug was not observed in the dialysis ﬂ  uid.
Geriatric patients
Plasma concentrations of rotigotine in patients 65 to 
80 years of age were similar to those in younger patients, 
approximately 40 to 64 years of age. Although not studied, 
exposures in older subjects (80 years) may be higher due 
to skin changes with aging.
Pediatric patients
The pharmacokinetics of rotigotine in subjects below the age 
of 18 years have not been established.
Pregnant and breastfeeding women
There are no adequate data from the use of rotigotine in preg-
nant women. Animal studies do not indicate any teratogenic 
effects in rats and rabbits, but embryo toxicity was observed 
in rats and mice at maternotoxic doses. The potential risk 
for humans is unknown. Rotigotine should not be used dur-
ing pregnancy. Rotigotine decreases prolactin secretion in 
humans and could potentially inhibit lactation. Studies in 
rats have shown that rotigotine and/or its metabolite(s) is 
excreted in breast milk. It is not known whether rotigotine 
is excreted in human breast milk. Because of the possibility 
that rotigotine may be excreted in human milk, and because 
of the potential for adverse reactions in nursing infants, a 
decision should be made whether to discontinue nursing or 
to discontinue the drug, taking into account the importance 
of the drug to the mother.
Clinical efﬁ  cacy, safety and tolerability
The evidence of the efﬁ  cacy of rotigotine in treating patients 
with Parkinson’s disease has led to the use of the drug in RLS 
patients. The ﬁ  rst pilot study to show proof-of-principle of 
rotigotine therapy in RLS was conducted by Stiasny-Kolster 
et al in 2004.94 Patients affected by moderate to severe idio-
pathic RLS and who had responded previously to levodopa 
were recruited in the trial. Three ﬁ  xed doses of rotigotine 
(1.125 mg, 2.25 mg, and 4.5 mg/daily) were compared with 
placebo over a period of 1 week. No dose titration was per-
formed. The primary efﬁ  cacy measure was the total score 
on the IRLS. Secondary endpoints were the RLS-6 scales Neuropsychiatric Disease and Treatment 2009:5 75
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and the Clinical Global Impression (CGI). A dose-response 
relationship was observed: RLS severity improved by 
10.5 (1.125 mg/die), 12.3 (2.25 mg/die), and 15.7 points 
(4.5 mg/die) in the IRLS compared with placebo (8 points). 
Higher improvements in the RLS-6 scales were also observed 
in patients treated with rotigotine compared with the placebo 
group in the severity of symptoms at bedtime or during the 
night. However, no differences were detected in the RLS-6 
quality of sleep and tiredness at daytime. Adverse events 
were rare and mild. The most common adverse event was 
the application site reaction seen in 26.5% of patients treated 
with rotigotine and in 28.6% of patients treated with placebo. 
Headache was the second most common side effect (22.4% 
of patients receiving rotigotine vs 7.1% of patients receiving 
placebo). Overall adverse events were more frequent in the 
two higher rotigotine dose groups (2.25 mg and 4.5 mg).
A longer trial with higher doses of rotigotine was con-
ducted in 2007 by Oertel et al in order to better investigate 
the beneﬁ  ts of rotigotine treatment in patients with idiopathic 
RLS.95 This was a randomized, multi-center, double-blind, 
placebo controlled 6-week trial using rotigotine patches with 
ﬁ  xed doses of 0.5 mg/24 hours (1.125 mg), 1 mg/24 hours 
(2.25 mg), and 2 mg/24 hours (4.5 mg), 3 mg/24 hours 
(6.75 mg), 4 mg/24 hours (9.0 mg). Study population con-
sisted of severely affected patients with a long history of RLS, 
who had been previously treated with dopaminergic drugs. 
Patients were randomly assigned to one of the six treatment 
groups and no drug dosage variations were allowed. Change 
in IRLS total score from baseline to the end of treatment 
was the primary efﬁ  cacy variable. The study showed a dose-
response relationship in the dose range 0.5 mg/24 hours and 
3 mg/24 hours. The 0.5 mg/24 hours dose was not statisti-
cally signiﬁ  cantly superior to placebo. The higher dosage 
(4 mg/24 hours) showed a minor improvement in the IRLS 
total score compared to 3 mg/24 hours. However, no differ-
ences were seen between the effects of 1 mg/24 hours and 
2 mg/24 hours. Other outcomes variables were the CGI, the 
RLS-6 scales and the QoL. Improvements in the CGI showed 
a similar dose-response relationship as seen with the IRLS. 
The RLS-6 scales showed an improvement of RLS symp-
toms at bedtime and during the night and a reduced tiredness 
during the day. As a consequence, the QoL improved in all 
treatment groups. The trial demonstrated how rotigotine 
improves RLS symptoms in a therapeutic window between 
1 mg/24 hours and 3 mg/24 hours. Despite the large placebo 
effect (responder rate of 42%) treatment with rotigotine in the 
therapeutic window cited above was demonstrated to be sta-
tistically superior in reducing RLS symptoms. Higher doses 
(4 mg/24 hours) have not demonstrated an additional beneﬁ  t 
and led to more adverse events. Adverse events were seen in 
62% of patients receiving rotigotine and in 45.5% of patients 
in the placebo group. Application site reaction was the most 
common side effect seen in 17.5% of patients receiving 
rotigotine and in 1.8% of patients receiving placebo. Serious 
adverse events were reported in 6 patients.
Of the 310 patients who ﬁ  nished this trial, 295 patients 
with a mean IRLS score of 27.8 ± 5.9 were included in an 
open label trial that observed long term (1 year) safety and tol-
erability of rotigotine.96 Patients were divided into 2 groups: 
those whose IRLS showed an improvement of at least 50% 
stopped treatment with rotigotine but could restart treatment 
by entering the trial if the clinical condition worsened; those 
who instead had shown minor improvements in the pervi-
ous trial entered immediately the second trial. Patients were 
excluded if severe adverse events had occurred or if they had 
not been compliant during the double blind study. Drug titra-
tion started with 0.5 mg/24 hours; the dose could be increased 
up to a maximum dose of 4 mg/24 hours. The mean daily 
dose after 12 months was 2.8 ± 1.2 mg/24 hours. Increases 
of the initial dose occurred in 51.7% of patients: once in 
27.2%, twice in 16.6%, 3–5 times in 7.9%. Dose adjustments 
occurred in the ﬁ  rst month of therapy but afterwards doses 
remained stable. Outcome parameters included the IRLS sum 
score, the RLS-6 scales, the CGI and the QoL-RLS. After 
12 months all these efﬁ  cacy parameters improved. A mean 
change in the IRLS total score of 17.4 was observed; 68% of 
the patients showed an improvement of at least 50% in the 
IRLS total score. For the RLS-6 severity scale, relief from 
symptoms at bedtime, during the night, during daytime when 
patients were at rest and reduced tiredness during the day 
were observed. This led to an improved QoL. Rotigotine was 
well tolerated, as only minor adverse events were observed. 
Application-site reaction occurred in 40% of patients but it 
was generally mild and could be resolved after changing the 
application site. Nausea and fatigue were the second most 
common side effects seen in 9.5% and 6.4% of patients, 
respectively.
Another trial was conducted in 2008 by Trenkwalder 
et al.97 The effects of rotigotine at the lowest levels of effec-
tiveness were studied over a period of 6 months. The study 
population consisted of patients affected by severe or very 
severe idiopathic RLS (mean IRLS sum score 28.1 ± 6.1), 
the majority of whom had been previously treated with dopa-
minergic drugs (71.1%). Patients were randomly assigned to 
receive placebo or rotigotine 1 mg/24 hours, 2 mg/24 hours, 
3 mg/24 hours. Efﬁ  cacy outcomes were: the IRLS sum score, Neuropsychiatric Disease and Treatment 2009:5 76
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the CGI, the RLS-6 scales, the QoL-RLS and the Medical 
Outcomes Study (MOS) sleep scale. At the end of the trial 
signiﬁ  cant improvements in the IRLS sum score and in the 
CGI were observed for all rotigotine dosages compared with 
placebo. The improvement observed showed a dose-response 
relationship, with the higher effects seen for the rotigotine 
3 mg/24 hours. Also the QoL improved with a dose-response 
relationship. Adverse events were seen in 77.7% of patients 
receiving rotigotine and in 55% of patients receiving pla-
cebo. As seen in previous trials, the most common adverse 
effect was application-site drug reaction (42.5% of patients 
receiving rotigotine).
Only 2 of the 4 trials evaluating the efﬁ  cacy of roti-
gotine transdermal delivery system in idiopathic RLS 
assessed the presence or severity of augmentation. Although 
standardized criteria to detect augmentation were not 
applied, Oertel et al did not report any patient with this 
adverse event.96 Trenkwalder et al observed similar scores at 
the Augmentation Severity Rating Scale – 4 items between 
placebo and each dose of rotigotine.97
Treatment of RLS with dopamine agonists has been infre-
quently associated with sudden and unintended sleep attacks.98 
Because sleep attacks under rotigotine treatment are infrequent 
and moderate in intensity, no patients with this adverse event 
discontinued the trial or changed the drug dose.94–97
Table 3 shows the main characteristics of the 4 trials on 
rotigotine in idiopathic RLS. The prevalence of the most 
frequent adverse events due to rotigotine and placebo in the 
4 trials is reported in Table 4.
As reported in Table 3, RLS patients recruited in trials on 
rotigotine showed a large placebo effect. Elevated placebo 
responder rates were also observed in almost all drug tri-
als conducted in RLS. The IRLS, which is considered the 
gold standard scale to assess RLS severity, is particularly 
prone to this condition. A possible explanation is that this 
tool includes items covering aspects that are not highly 
Table 3 Main characteristics of the four trials on rotigotine in idiopathic RLS (IRLS)
Stiasny-Kolster et al 200494 Oertel et al 200895 Oertel et al 200896 Trenkwalder et al 200897
Trial Randomized, double-blind, 
placebo-controlled, 
multi-center trial
Randomized, double-
blind, placebo-controlled, 
multi-center trial
Open label, single 
arm, multi-center 
trial
Randomized, double-
blind, placebo-
controlled trial
Study duration 1 week 6 weeks 1 year 6 months
Number of pts
(ITT population)
63 333 295 447
Age of pts 58.3 ± 8.8 58.4 ± 10.3 58.0 ± 10.0 57.7 ± 11.1
Sex, female (%) 63.5 67.3 66.0 71.1
Duration of RLS (yr) 10.5 ± 9.5 11.0 (median) 11.0 (median) n.a.
Previous dopaminergic 
treatment (%)
85.7 (levodopa) 
15.9 (DA)
72.4 (levodopa) 
40.5 (DA)
72.4 (levodopa) 
40.5 (DA)
71.1
Previously untreated (%) 12.7 19.2 19.2 27.9
IRLS severity 25.9 ± 5.1 
(range 16–38)
27.9 ± 6.0 27.8 ± 5.9 28.1 ± 6.1 
(range 15–40)
Daily rotigotine dosage 0.5 mg/24 h 
1 mg/24 h 
2 mg/24 h
0.5 mg/24 h 
1 mg/24 h 
2 mg/24 h 
3 mg/24 h 
4 mg/24 h
Mean daily dose 
2.8 ± 1.2 mg/24 h
1 mg/24 h 
2 mg/24 h 
3 mg/24 h
Primary efﬁ  cacy 
measure
IRLS IRLS IRLS IRLS
Secondary endpoints RLS-6, CGI RLS-6, CGI, 
QoL-RLS
RLS-6, CGI, 
QoL-RLS
RLS-6, CGI, 
QoL-RLS, MOS
Mean change from 
baseline in the 
IRLS sum score
10.5 pointsa 
12.3 pointsb 
15.7 pointsc 
8 pointsf
10.6 pointsa 
15.1 pointsb 
15.7 pointsc 
17.5 pointsd 
14.8 pointse 
9.2 pointsf
Mean change of 
17.4 points
13.7 pointsb 
16.2 pointsc 
16.8 pointsd 
8.6 pointsf
Mean IRLS change for: a0.5 mg/24 hours; b1 mg/24 hours; c2 mg/24 hours; d3 mg/24 hours; e4 mg/24 hours; fplacebo.Neuropsychiatric Disease and Treatment 2009:5 77
Rotigotine for RLS
speciﬁ  c for RLS, such as sleep quality, daytime tiredness, 
mood and quality of life.99
Regulatory affairs
Rotigotine was approved by the FDA for treatment of early 
Parkinson’s disease and by the EMEA for treatment of all 
stages of Parkinson’s disease. The drug has been recommended 
for approval by the EMEA and is under review by the FDA for 
the treatment of moderate to severe idiopathic RLS. Recently, 
rotigotine has been recalled because of the formation of drug 
crystals in the patches. Due to crystal formation, in these 
patches rotigotine is less available to be absorbed through the 
skin, thus the efﬁ  cacy of the affected product may vary.
Discussion and Conclusion
RLS is one of the most common neurological disorders and, 
if severe, it may affect the patient’s life, impairing physical 
and mental health. Although diagnosis of RLS is clinical and 
based on internationally recognized clinical criteria, it is not 
always easy, in particular when physicians are not familiar 
with this sleep disorder. In order to increase the sensibility 
and speciﬁ  city of RLS diagnosis, physicians should perform 
a careful patient history and then a meticulous physical and 
neurological examination.
Patients affected by severe and frequent symptoms of RLS 
should receive pharmacological treatment. In subjects with 
RLS associated with iron deﬁ  ciency (serum ferritin levels 
lower than 50 μg/L) an attempt with replacement treatment 
is mandatory. Intravenous iron is likely more effective in 
improving RLS symptoms than oral iron. The adverse events 
due to oral (eg, gastrointestinal disturbances) and intravenous 
(eg, anaphylaxis) iron, and a possible risk for hemochroma-
tosis should be carefully considered by physicians.
Patients affected by idiopathic RLS should be treated 
with dopaminergic agents (non-ergoline dopamine agonists 
and levodopa), that are considered to be ﬁ  rst-line therapy. 
Table 4 Prevalence of the most frequent adverse events due to rotigotine and placebo in the four trials
Stiasny-Kolster 
et al 200494
Oertel et al 200895 Oertel et al 
200896
Trenkwalder et al 200897
Rotigotine Placebo Rotigotine Placebo Rotigotine Rotigotine Placebo
Any adverse 
event (%)
n.a. n.a. 64.7a 
48.4b 
57.1c
75.4d 
64.3e
45.5 79.0 73b 
80c 
80d
55
Any serious 
adverse event (%)
n.a. n.a. 2.0a 
1.6b 
0.0c
3.1d 
0.0e
1.8 7.8 6.0b 
4.0c 
11.0d
4.0
Application site 
reaction (%)
17.6a 
38.5b 
26.3c
28.6 9.8a 
15.6b 
16.3c
20.0d 
25.0e
1.8 40.0 35.0b 
41.0c 
52.0d
2.0
Headache (%) 11.8a 
38.5b 
21.1c
7.1 11.8a
7.8b 
2.0c
4.6d 
12.5d
7.3 4.1 10.0b 
13.0c 
16.0d
7.0
Nausea (%) 0.0a 
7.7b 
5.3c
14.3 5.9a 
9.4b 
6.1c
24.6d 
23.2e
9.1 9.5 9.0b 
21.0c 
18.0d
3.0
Fatigue (%) 0.0a 
0.0b 
10.5c
0.0 3.9a 
4.7b 
6.1c
10.8d 
7.1e
9.1 6.4 7.0b 
15.0c 
11.0d
9.0
Pruritus (%) 5.9a 
15.4b 
0.0c
7.1 5.9a 
3.1b 
0.0c
10.8d 
3.6e
1.8 n.a. n.a. n.a.
Insomnia (%) 0.0a 
7.7b 
5.3c
7.1 n.a. n.a. 3.7 0.0b 
0.0c 
7.0d
3.0
Hyperhidrosis (%) 0.0a 
0.0b 
10.5c
0.0 n.a. n.a. n.a. 5.0b 
6.0c 
4.0d
3.0
Prevalence of adverse events for: a0.5 mg/24 hours; b1 mg/24 hours; c2 mg/24 hours; d3 mg/24 hours; e4 mg/24 hours.Neuropsychiatric Disease and Treatment 2009:5 78
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In subjects with RLS not complaining of daytime symptoms, 
oral non-ergoline dopamine agonists or levodopa should be 
preferred. These compounds are able to control RLS symp-
tomatology also when present during daytime, but, because of 
their short half-life, patients should take the medications many 
times during the day. This condition might signiﬁ  cantly reduce 
treatment compliance. Thus, we think that RLS patients com-
plaining of daytime symptoms might beneﬁ  t from a medication 
with continuous delivery, such as transdermal patches of roti-
gotine. However, the effectiveness and safety of dopaminergic 
compounds administered via different routes in treating RLS 
might be dissimilar. Comparative trials are needed.
Based on clinical trails and our experience, rotigotine 
seems to control the symptomatology effectively and to be 
well tolerated when used in patients with this sleep disorder. 
In particular, RLS symptoms are generally improved by roti-
gotine in a therapeutic window between 1 mg/24 hours and 
3 mg/24 hours. If necessary, a higher dose of 4 mg/24 hours 
should be administered. Application-site reactions, headache 
and nausea may be reported, but these adverse events are 
generally moderate in intensity and patients do not need to 
stop their treatment. Although based on a few clinical trials, 
augmentation and sleep attacks do not appear to be common 
adverse effects of rotigotine when used for RLS patients.
If augmentation occurs under rotigotine or another dopa-
mine agonist, physicians should reduce or split the dosage. 
Alternatively, a therapeutic change with opioids/gabapentin 
or a combination therapy administering very low doses of 
dopamine agonists with opioids/gabapentin should be consid-
ered. For the occurrence of augmentation under levodopa at 
lower range of recommended doses, the physician should try 
to split the medication into 2 doses, 1 given in the afternoon 
and 1 in the evening. Alternatively a longer-acting dopami-
nergic agent should be administered. To treat augmentation 
during higher dosages of levodopa, the physician should 
switch to dopamine agonists.
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